PNB Vesper gets nod to begin phase-2 clinical trials for COVID-19 drug
The molecule was initially developed for lung cancer, the company's promoter and chief executive P N Balaram told . The firm's labs are located in Britain. He said the company on Thursday received permission from the Central Licensing Authority under the Central Drugs Standard Organisation for the second phase of clinical trials.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Clinical Trials | COVID-19 | Lung Cancer | Pharmaceuticals | UK Health